Komori
Japan Tobacco (2914) · RiskFirst stated

Dependence on Specific Licensing and Contract Manufacturing Partners

First written in FY2024. . Latest entry: FY2024.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Reliance on External Partners, Including Licensors, Sales Partners and CROsA theme 105 companies write about · 108 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2020: 9 of 44 companies on the "Worse" side.

10 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 105 companies compared. The sentences above are computed from all 105.
Full recordFilings, disclosures and news, newest first
  1. FY2024First statedAnnual report

    「The manufacture of each product is outsourced, and we maintain close cooperation with these partners. If contracts with our partners are changed or terminated, if cooperation is delayed or disrupted, or if it fails to generate the returns expected at the time the contracts were entered into or the returns are delayed, the performance of our Group could be adversely affected.」

    The pharmaceutical business identifies its dependence on licensing partners and external contract manufacturers, and the impact on performance of changes to or termination of contracts and delays in partnerships, as standalone risks.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Japan Tobacco's next results are scheduled for 2026-10-29. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.